724788-66-3

Upstream product

• 724788-65-2 4-bromo-6-methoxy-1,5-naphthyridine-3-carboxylic acid 
• 75-65-0 tert-butyl alcohol 
• 1417551-48-4 t-butyl 4-bromo-6-methoxy-1,5-naphthyridine-3-yl-carbamate 
• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 724788-64-1 ethyl 4-bromo-6-methoxy-1,5-naphthyridine-3-carboxylate 
• 724788-63-0 ethyl 6-methoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxylate 
• 53241-92-2 4-Hydroxy-6-methoxy-[1,5]naphthyridine-3-carboxylic Acid Ethyl Ester 
• 53241-90-0 diethyl {[(6-methoxypyridin-3-yl)amino]methylidene}propanedioate 
• 724788-67-4 (4-bromo-6-methoxy-[1,5]naphthyridin-3-ylamino)carbamic acid tert-butyl ester 

Downstream Products

• 724788-70-9 8-bromo-7-fluoro-2-methoxy-1,5-naphthyridine 
• 1616409-89-2 t-butyl 1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylcarbamate 
• 1616409-88-1 t-butyl 1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylcarbamate 
• 1415415-01-8 7-fluoro-2-methoxy-8-methyl-1,5-naphthyridine 

Relevant academic research and scientific papers

Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents

Bacterial resistance is eroding the clinical utility of existing antibiotics necessitating the discovery of new agents. Bacterial type II topoisomerase is a clinically validated, highly effective, and proven drug target. This target is amenable to inhibit

BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.

Novel amino-piperidines as potent antibacterials targeting bacterial type IIA topoisomerases

We have identified a series of amino-piperidine antibacterials with a good broad spectrum potency. We report the investigation of various subunits in this series and advanced studies on compound 8. Compound 8 possesses good pharmacokinetics, broad spectrum antibacterial activity and demonstrates oral efficacy in a rat lung infection model.

Antibacterial Agents

Naphthalene, quinoline, quinoaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

ANTIBACTERIAL AGENTS

Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

ANTIBACTERIAL AGENTS

Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

ANTIBACTERIAL AGENTS

Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

ANTIBACTERIAL AGENTS

Naphthyridine and related derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

ANTIBACTERIAL AGENTS

Naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

ANTIBACTERIAL AGENTS

Naphthyridine and related derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.